Biowave

Percutaneous Electrical Nerve Stimulation (PENS)

Percutaneous Electrical Nerve Stimulation (PENS)

“The Biowave PENS units made an immediate and sustained positive impact on our practice.  Our patients are experiencing significant reductions in pain and the system could not be easier to use and store.  Biowave and DynaMD have been great to work with and the units paid for themselves in just a few months.  Would highly recommend the Biowave units to any practice/facility that may be considering them.  Great product.”

Neuro-Spine Solutions

Biowave

Biowave’s neuromodulation pain therapy medical devices deliver a patented therapeutic electrical signal into deep tissue in the body which blocks the transmission of pain and improves function. Multiple clinical studies including double blinded randomized crossover studies have shown that a 20-30 minute treatment provides patients with significant benefits including:

  • Up to an immediate 75% average reduction in pain
  • 24 to 48 hours of pain relief
  • Increase in range of motion
  • Reduction of stiffness
  • Reduction of muscle spasm

Biowave’s advanced, patented signal mixing technology allowed for the design of a very easy to use device – there is no programming – the signals coming out of the device are optimized for passing through the skin into deep tissue and for inhibiting pain transmission.

Additionally, Biowave’s SmartPAD™ technology is used in every electrode made by the Company. SmartPAD™ electrodes allow for the continuous monitoring and adjustment of the electrical signal technology ensuring the accurate and safe delivery of therapeutic energy into deep tissue.

All of Biowave’s neuromodulation pain therapy systems treat joint or muscular related chronic, acute or post-surgical pain in the low back, shoulder, neck, hip, knee, elbow, legs, arms, wrist, hands, ankles and feet, without harmful side effects. Use of Biowave devices reduces the need for morphine, narcotics and other painkillers, resulting in better quality of life scores.

Biowave’s patented percutaneous electrode array (PEA) is a microneedle patch technology that facilitates the delivery of high frequency electrical feed signals through the skin directly into deep tissue encompassing the pain site. The PEA eliminates impedance and capacitance issues associated with skinPercutaneous Electrode Array

Patented Neuromodulation Signal Technology

biowave peaThe patented electrical signal technology is comprised of a premixed set of high frequency wave forms which are delivered to each electrode. As the feed signals pass through each electrode which are placed directly over points of pain, polarized structures including nerve fiber membranes, that lie within a two inch volume of tissue beneath each electrode, act like nonlinear devices, causing the feed signals to further multiply. The result is a new spectrum of signals including the formation of a low frequency electric field, which is believed to interrupt transmission of pain impulses by preventing action potential propagation along pain fibers – a similar mechanism to local chemical anesthesia, except without any deleterious side effects.

The use of different sized pads as well as the use of a percutaneous electrode in combination with a non-invasive electrode allow the resulting electric field to be focused in the volume of tissue surrounding and beneath the PEA (see top diagram to the right). The size of the volume of tissue affected can be changed and is dependent upon PEA placement, geometry and materials, as well as the intensity of the feed signals. The sensation felt by the patient is a comfortable pressure and tingling sensation without muscle twitching or side effects that are common to other electrotherapy devices.

Biowave also utilizes its patented SmartPAD™ technology in all of its electrodes. The SmartPAD™ technology is a continuous closed loop monitoring and adjustment of the delivery of the electrical signal technology. The SmartPAD™ technology ensures the accurate and safe delivery of therapeutic energy into deep tissue.